CYTOKINETICS INC Q2 FY2025 earnings call

Robert Blum discussed progress on aficamten's NDA, including FDA PDUFA date extension to December 26, 2025, late-cycle review meeting moved to September, completed GCP inspections, and ongoing dialogue with FDA. Also mentioned regulatory reviews in Europe and China for aficamten. Andrew Callos talked about commercial launch readiness, hiring a U.S. sales force with over 8,800 applications and hiring experienced cardiovascular sales professionals, optimizing distribution network, advancing patient support program, and payer engagement. Fady Malik provided updates on MAPLE-HCM positive top line results, ACACIA-HCM completion of patient enrollment, and other clinical trials for aficamten. Stuart Kupfer gave updates on omecamtiv mecarbil's COMET-HF trial enrollment progress and ulacamten's AMBER-HFpEF trial enrollment. Sung Lee reported Q2 2025 financial results, with cash, cash equivalents and investments at ~$1.04B, R&D expenses at $112.6M, G&A expenses at $65.7M, and net loss at $134.4M.

No specific product segment financial performance data on absolute terms and revenue contribution % provided in the transcript.

Maintains full year 2025 financial guidance with GAAP operating expense expected to be between $670 million and $710 million. Stock-based compensation included in GAAP operating expense is expected to be between $110 million and $120 million. Excluding stock-based compensation, GAAP operating expense ranges from $550 million to $600 million. Upcoming milestones include advancing NDA review for aficamten in U.S. second half 2025, launch preparations for U.S., go-to-market planning in Germany and Europe, coordinating with Sanofi for China approval, presenting MAPLE-HCM results at ESC, reporting ACACIA-HCM top line results in first half 2026, enrolling Japan cohort of ACACIA-HCM in 2025, completing enrollment of adolescent cohort in CEDAR-HCM in second half 2025, continuing enrollment in COMET-HF in 2025, and completing enrollment of first 2 patient cohorts in AMBER-HFpEF in second half 2025.

Portions of the discussion contain forward-looking statements, and actual results might differ materially from projected. Additional information concerning factors that could cause actual results to differ materially is in SEC filings, and no obligation to update forward-looking statements after the call.

Q: Regarding the ESC update and magnitude of benefit for MAPLE data, can you elaborate?

A: Fady mentioned MAPLE-HCM is a comparative efficacy trial, data will show difference between aficamten and metoprolol and their absolute benefits compared to baseline, and waiting for data to expand on details.

Q: What are 2 or 3 things investors should look at in Camzyos ODYSSEY data related to ACACIA?

A: Robert and Fady discussed trial conduct differences, ACACIA's optimized dosing regimen, population focus, and mechanism of action relevance to patient population.

Q: What does an ideal label for aficamten in obstructive HCM look like?

A: Robert mentioned ideal label tracks with engineered properties and study results, Andrew talked about market research showing high awareness of aficamten in HCM specialized centers and market research supporting expanded prescribing.

Q: What to expect in the September late-cycle meeting for aficamten?

A: Robert hopes to learn proceeding to final label conversations with no new issues, as Cytokinetics was prepared for REMS submission after FDA's interest.

Q: How do drug interruptions and discontinuation protocols differ between ACACIA and ODYSSEY?

A: Fady explained differences in EF thresholds, dosing strategies, and patient population considerations between the two trials.

Q: Expectations on REMS differences between U.S. and EU?

A: Robert stated EU doesn't have formal REMS, but labels will have common elements in risk mitigation, drug-drug interaction, etc.

Q: Larger market opportunity in nonobstructive HCM and sales force expansion?

A: Andrew said initial sales force focus on HCM specialized centers, and expansion if more is learned about nHCM population.

Q: Strategies for patient access against Camzyos?

A: Andrew mentioned parity of access in commercial and Medicare, with patient support programs targeted to be at par or better, differentiating on clinical data, REMS, and patient experience.

Q: Similarities and differences in European launch preparation?

A: Andrew discussed country-by-country launch, reimbursement on a country-by-country basis, focus on German launch first, and differences in REMS and prescribing focus compared to U.S.

Q: What a win looks like for HFpEF and relation to nonobstructive HCM?

A: Stuart mentioned evaluating symptomatic improvement, cardiac biomarkers, and echocardiographic parameters in AMBER-HFpEF, with parallels to nonobstructive HCM findings.

Q: Message to lead with in HCM commercialization?

A: Robert and Andrew stated messaging will align with label and promotion to label, focusing on clinical data, REMS, and patient experience.

Q: China market dynamics and revenue cadence for aficamten?

A: Andrew said uptake likely slow at start with cash paying market, but acceleration expected once national drug reimbursement occurs, with Sanofi's expertise in the market.

Q: Components of commercial preparations related to REMS and COMET trial site excitement?

A: Robert said preparations aligned with FDA's REMS expectations, and Stuart mentioned high investigator interest in COMET-HF due to unmet need, GALACTIC results, and streamlined trial conduct.

Q: Expectations for first-line use of aficamten and payer/requester receptiveness?

A: Fady and Andrew discussed that while beta blockers are generic, MAPLE-HCM data may facilitate earlier movement in guidelines, with initial acceleration of add-on use and potential weaning off beta blockers over time.

Q: Differentiating factors of cardiac myosin inhibitors from a biology perspective?

A: Fady explained different binding sites of aficamten, omecamtiv mecarbil, and ulacamten, leading to distinct effects on sarcomere function and potential clinical profiles.

Q: Impact of late-cycle meeting push from June to September on PDUFA date?

A: Robert stated the shift is consistent with PDUFA date extension, and no reason to believe it affects hopeful approval.